Sky-high drug prices could hurt Republicans in 2020

Drug prices are still rising, with manufacturers hiking up prices at the start of 2020. And the “reluctance” from the Republican party to challenge those rising prices could become a huge liability for the upcoming 2020 election, according to The Hill.

That’s because the Trump administration made lowering drug prices a huge cornerstone of its healthcare agenda, releasing a blueprint early on in the administration’s control and proposing several modest policies that could lower the cost of some prescription drugs under Medicare. However, critics have pointed out that another recent proposal to import some drugs from Canada at lower prices might not actually work.

In addition, Republicans are staunchly against legislation that would actually limit what drugmakers are allowed to charge for drugs––something other countries actively do to keep costs in check. Further, Senate Majority Leader Mitch McConnell (R-KY) refuses to hold votes for several bipartisan bills that would impact drug prices.

“But as Republicans fight to keep control of the Senate, doing nothing on an issue of vast importance to voters is also a gamble,” the report from The Hill reads.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”